Equities
Health CareMedical Equipment and Services
  • Price (USD)158.26
  • Today's Change6.77 / 4.47%
  • Shares traded684.55k
  • 1 Year change-13.75%
  • Beta1.1168
Data delayed at least 15 minutes, as of Aug 10 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Company provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its products under various brand names, including AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, Chitas, Datalytix, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROline, EUROPattern, FragilEase, Genoglyphix, GSP, and others.

  • Revenue in USD (TTM)5.02bn
  • Net income in USD674.23m
  • Incorporated1947
  • Employees16.70k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Integra Lifesciences Holdings Corp1.57bn166.30m4.59bn3.80k28.032.7616.022.931.961.9618.4819.890.41981.776.45412,325.804.463.264.853.6163.5864.2110.617.362.766.870.48250.0012.439.2326.2817.790.3158--
MKS Instruments, Inc.3.01bn555.60m6.17bn6.00k11.111.979.252.059.979.9754.0456.180.67272.696.57502,133.3012.4011.3013.7512.5845.6445.9318.4415.913.6329.710.206612.1426.5917.8957.5039.3835.304.81
Cognex Corporation1.09bn258.67m7.97bn2.26k31.645.7428.657.341.451.456.118.020.54743.796.69481,146.7013.0415.1714.4916.4071.2974.2723.8228.483.32--0.0044.8727.8814.3958.8614.223.8210.68
Bruker Corporation2.48bn273.90m8.94bn7.77k33.469.2224.533.611.801.8016.336.540.76511.646.69318,840.908.537.6811.8310.5050.7447.9411.149.571.6225.470.544712.9621.668.4675.6012.5319.920.00
Bio Rad Laboratories Inc2.87bn-1.94bn15.41bn7.90k--1.73--5.37-66.32-66.3295.80300.450.20661.966.76363,415.10-13.9724.42-14.6126.3657.0555.45-67.6683.244.220.16680.11830.0014.817.1611.55177.08-3.10--
Avantor Inc7.60bn572.10m18.78bn13.50k31.654.2019.152.470.88030.880311.796.630.61615.675.99563,170.405.09--5.79--34.2132.518.272.421.054.660.594--15.5260.60876.92--30.02--
PerkinElmer, Inc.5.02bn674.23m19.11bn16.70k27.922.6716.973.815.435.4240.5756.820.43794.035.22300,600.005.886.636.497.7054.3152.3113.4314.321.428.130.38516.5533.9519.0929.5534.3225.800.00
Waters Corporation2.90bn702.12m19.39bn7.80k28.2249.5423.186.6811.4711.4747.416.540.94423.204.91371,868.3022.8516.2029.7719.4458.1158.4824.2124.161.5524.150.7910.0017.785.1532.845.8512.12--
Fortive Corp5.52bn658.60m23.10bn18.00k35.822.4521.094.191.811.8015.1826.560.36094.546.27306,422.204.315.235.196.4157.3955.0011.9415.080.72679.600.280414.0613.38-0.4635-58.09-4.77-14.6014.87
AMETEK, Inc.5.92bn1.09bn28.66bn18.50k26.544.1220.454.844.704.7025.4430.270.49854.616.50319,865.009.228.8410.8010.2034.6236.2018.4916.730.884917.510.264716.8822.177.6313.4814.0911.8317.32
Keysight Technologies Inc5.14bn1.02bn29.24bn14.50k29.407.7423.285.695.535.5327.7921.010.66552.346.95359,510.5013.247.6815.989.2563.9658.1719.9011.732.2616.640.32170.0017.0611.1142.5821.6913.84--
Mettler-Toledo International Inc.3.87bn820.63m29.59bn15.60k37.044,074.3431.737.6535.4935.49167.190.32271.193.966.30247,779.9025.3321.4337.1130.0758.3258.0021.2318.720.770122.370.99630.0020.518.1927.5814.88-2.79--
Illumina, Inc.4.66bn700.00m33.75bn9.80k46.853.1033.957.254.584.5830.2369.390.38753.508.12475,102.005.8310.936.5812.9668.8168.8115.0323.161.54--0.13770.0039.7313.5416.1610.49-5.15--
Data as of Aug 10 2022. Currency figures normalised to PerkinElmer Inc's reporting currency: US Dollar USD

Institutional shareholders

56.90%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 202214.95m11.85%
Capital Research & Management Co. (Global Investors)as of 31 Mar 202214.32m11.35%
The Vanguard Group, Inc.as of 31 Mar 202213.23m10.49%
BlackRock Fund Advisorsas of 31 Mar 20226.16m4.88%
Select Equity Group LPas of 31 Mar 20225.73m4.54%
SSgA Funds Management, Inc.as of 31 Mar 20225.16m4.09%
Massachusetts Financial Services Co.as of 31 Mar 20224.18m3.31%
Pictet Asset Management SAas of 31 Mar 20223.54m2.81%
Geode Capital Management LLCas of 31 Mar 20222.43m1.93%
Janus Henderson Investors US LLCas of 31 Mar 20222.09m1.65%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.